Aktiia demonstrates new way to lower BP

Individuals using Aktiia 24/7 cuffless monitor persistently for 6 months achieve a reduction in BP.

The Aktiia 24/7 Blood Pressure Monitor includes the Aktiia App and Bracelet

On September 9, 2022, in San Diego at the AHA Hypertension Sessions, Aktiia presented the results of an analysis co-authored by experts from Barts NIHR Biomedical Research Centre (London, UK), Scripps Translational Research Institute (La Jolla, USA), Lausanne University Hospital (Lausanne, CH), Brigham and Women’s Hospital (Boston, USA), and Mayo Clinic (Phoenix, USA) demonstrating that hypertensive patients who monitor their blood pressure (BP) with Aktiia’s 24/7 BP monitor achieve a significant and sustained reduction in systolic BP. Aktiia’s optical continual BP monitor has been available for purchase in seven European countries since March 2021. By design and purpose, Aktiia’s passive and continual collection of BP data has quickly compiled over 55,000,000 data points in real-world conditions, establishing the largest dataset of BP readings in the world which uniquely enables Aktiia and its partners to unlock new insights into hypertension.

The objective of Aktiia’s recent investigation was to explore whether a change in behaviour resulting in measurably lower BP would be demonstrated in hypertensive subjects who were consistently exposed to their BP data via Aktiia’s integrated mobile app. The analysis concluded that mean SBP was reduced in -3.2 mmHg (confidence interval: [-0.70, -5.59], p<0.02) for hypertensive users (SBP > 140 mmHg) following 3 months of continual cuffless BP monitoring (Figure 2). This reduction was then sustained throughout the 6 months studied. Mean SBP remained unchanged for normotensive users (SBP < 140 mm Hg).

The powerful relationship between BP reduction and reduction of cardiovascular events is undisputed, irrespective of the mechanism for the reduction. Even a 5 mm Hg reduction in systolic BP reduces cardiovascular risk by 10%. By using Aktiia consistently, people were not only made aware of their condition but were empowered to make changes to their behaviour which achieved an effect similar to that of a medication. Aktiia will continue to expand research that investigates the factors contributing to this reduction in blood pressure, and work to augment these benefits among the Aktiia user population. These data highlight just the beginning of the tremendous value of Aktiia’s dataset across the hypertension care continuum.

Results from Aktiia’s investigation, showing reduction in Systolic Blood Pressure for hypertensive users

Jürgen Thalmayer
September 14, 2022

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

Vitality and New Strategic Partners Focus on Diabetes Prevention and Management and Financial Wellness

Vitality Group, a global health and wellness company committed to making people healthier.

Sooma Medical Receives FDA Breakthrough Designation

The neuromodulation device has been granted this designation by the FDA for depression treatments.

Solos Health Announces Early Fever Detection Technology ‘FeverGuard’

Solos Health Analytics, an innovator in health and wellness, introduced FeverGuard.....

VRSim’s Cutting Edge VRNA EMS Training Product

VRNA EMS provides immersive training for Emergency Medical Professionals and First Responders.
Discover more